SER recommendations on the use of biological drugs in primary Sjögren's syndrome

Brito-Zeron, 2016, Sjogren syndrome, Nat Rev Dis Primers, 2, 16047, 10.1038/nrdp.2016.47 Goules, 2017, Primary Sjogren's syndrome: clinical phenotypes, outcome and the development of biomarkers, Immunol Res, 65, 331, 10.1007/s12026-016-8844-4 Fayyaz, 2016, Autoantibodies in Sjogren's syndrome, Rheum Dis Clin North Am, 42, 419, 10.1016/j.rdc.2016.03.002 Qin, 2015, Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis, Ann Rheum Dis, 74, 1983, 10.1136/annrheumdis-2014-205375 Ramos-Casals, 2008, Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients, Medicine (Baltimore), 87, 210, 10.1097/MD.0b013e318181e6af Fernandez Castro, 2016, Sjogren SER: national registry of the Spanish Society of Rheumatology of patients with primary Sjogren syndrome: objectives and methodology, Reumatol Clin, 12, 184 Vitali, 2002, Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group, Ann Rheum Dis, 61, 554, 10.1136/ard.61.6.554 Shiboski, 2017, 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: a consensus and data-driven methodology involving three international patient cohorts, Ann Rheum Dis, 76, 9, 10.1136/annrheumdis-2016-210571 Zhang, 2017, Sjogren's syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence from short form 36 questionnaire and a meta-analysis, Patient Prefer Adherence, 11, 905, 10.2147/PPA.S132751 Fernandez Castro, 2010, Etiologic treatment of sicca syndrome. What can the rheumatologist offer? [artículo en español], Reumatol Clin, 6, 1 Miyawaki, 1999, Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren's syndrome, Intern Med, 38, 938, 10.2169/internalmedicine.38.938 Wang, 2017, Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis, BMC Musculoskelet Disord, 18, 186, 10.1186/s12891-017-1543-z Skopouli, 1996, Methotrexate in primary Sjogren's syndrome, Clin Exp Rheumatol, 14, 555 Van Woerkom, 2007, Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot study, Ann Rheum Dis, 66, 1026, 10.1136/ard.2006.060905 ter Borg, 2002, Treatment of primary Sjogren's syndrome with D-penicillamine: a pilot study, Neth J Med, 60, 402 Price, 1998, A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome, J Rheumatol, 25, 896 Drosos, 1986, Cyclosporin A (CyA) in primary Sjogren's syndrome: a double blind study, Ann Rheum Dis, 45, 732, 10.1136/ard.45.9.732 Cummins, 2003, Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results, Arthritis Rheum, 49, 585, 10.1002/art.11199 Willeke, 2007, Mycophenolate sodium treatment in patients with primary Sjogren syndrome: a pilot trial, Arthritis Res Ther, 9, 10.1186/ar2322 Ciurtin, 2015, Advances in the treatment of ocular dryness associated with Sjogrens syndrome, Semin Arthritis Rheum, 45, 321, 10.1016/j.semarthrit.2015.06.007 Foulks, 2015, Clinical guidelines for management of dry eye associated with Sjogren disease, Ocul Surf, 13, 118, 10.1016/j.jtos.2014.12.001 Lopez-Pintor, 2015, Oral involvement in patients with primary Sjogren's syndrome. Multidisciplinary care by dentists and rheumatologists, Reumatol Clin, 11, 387 Nishishinya, 2015, Identification of lymphoma predictors in patients with primary Sjogren's syndrome: a systematic literature review and meta-analysis, Rheumatol Int, 35, 17, 10.1007/s00296-014-3051-x Brito-Zeron, 2016, Systemic activity and mortality in primary Sjogren syndrome: Predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients, Ann Rheum Dis, 75, 348, 10.1136/annrheumdis-2014-206418 Kiripolsky, 2017, Innate immunity in Sjogren's syndrome, Clin Immunol, 182, 4, 10.1016/j.clim.2017.04.003 Sankar, 2004, Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial, Arthritis Rheum, 50, 2240, 10.1002/art.20299 Zandbelt, 2004, Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study, J Rheumatol, 31, 96 Mariette, 2004, Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS), Arthritis Rheum, 50, 1270, 10.1002/art.20146 Steinfeld, 2001, Infliximab in patients with primary Sjogren's syndrome: a pilot study, Arthritis Rheum, 44, 2371, 10.1002/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W Steinfeld, 2002, Infliximab in primary Sjogren's syndrome: one-year followup, Arthritis Rheum, 46, 3301, 10.1002/art.10674 Steinfeld, 2013, Notice of retraction of two articles («Infliximab in patients with primary Sjogren's syndrome: a pilot study» and «Infliximab in patients with primary Sjogren's syndrome: One-year followup»), Arthritis Rheum, 65, 814, 10.1002/art.37942 Cornec, 2012, B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment, J Autoimmun, 39, 161, 10.1016/j.jaut.2012.05.014 Nocturne, 2015, Sjogren Syndrome-associated lymphomas: an update on pathogenesis and management, Br J Haematol, 168, 317, 10.1111/bjh.13192 Souza, 2016, Rituximab effectiveness and safety for treating primary Sjogren's syndrome (pSS): systematic review and meta-analysis, PLOS ONE, 11, 10.1371/journal.pone.0150749 Dass, 2008, Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study, Ann Rheum Dis, 67, 1541, 10.1136/ard.2007.083865 Devauchelle-Pensec, 2014, Treatment of primary Sjogren syndrome with rituximab: a randomized trial, Ann Intern Med, 160, 233, 10.7326/M13-1085 Meijer, 2010, Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 62, 960, 10.1002/art.27314 Carubbi, 2013, Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study, Arthritis Res Ther, 15, 10.1186/ar4359 Pijpe, 2005, Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study, Arthritis Rheum, 52, 2740, 10.1002/art.21260 Seror, 2007, Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome, Ann Rheum Dis, 66, 351, 10.1136/ard.2006.057919 Mekinian, 2012, Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry, Ann Rheum Dis, 71, 84, 10.1136/annrheumdis-2011-200086 Gottenberg, 2013, Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the autoimmune and rituximab registry, Ann Rheum Dis, 72, 1026, 10.1136/annrheumdis-2012-202293 Letaief, 2018, Efficacy and safety of biological DMARDs modulating B cells in primary Sjogren's syndrome: Systematic review and meta-analysis, Joint Bone Spine, 85, 15, 10.1016/j.jbspin.2017.06.004 Bowman, 2017, Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome, Arthritis Rheumatol, 69, 1440, 10.1002/art.40093 Fisher, 2018, Effect of rituximab on a salivary gland ultrasound score in primary Sjogren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy, Ann Rheum Dis, 77, 412, 10.1136/annrheumdis-2017-212268 Mariette, 2003, The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome, Ann Rheum Dis, 62, 168, 10.1136/ard.62.2.168 Quartuccio, 2013, BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands, Rheumatology (Oxford), 52, 276, 10.1093/rheumatology/kes180 Quartuccio, 2008, Resistance to rituximab therapy and local BAFF overexpression in Sjogren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma, Open Rheumatol J, 2, 38, 10.2174/1874312900802010038 Furie, 2011, A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis Rheum, 63, 3918, 10.1002/art.30613 Navarra, 2011, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet, 377, 721, 10.1016/S0140-6736(10)61354-2 Mariette, 2015, Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study, Ann Rheum Dis, 74, 526, 10.1136/annrheumdis-2013-203991 De Vita, 2015, Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study, Rheumatology (Oxford), 54, 2249 Quartuccio, 2016, Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjogren's syndrome: follow-up after the end of the phase II open-label BELISS study, Clin Exp Rheumatol, 34, 311 Seror, 2015, Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjogren's syndrome: results of the BELISS study, Arthritis Res Ther, 17, 241, 10.1186/s13075-015-0750-y Halse, 1999, Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjogren's syndrome, Scand J Immunol, 49, 533, 10.1046/j.1365-3083.1999.00533.x Tishler, 1999, Increased salivary interleukin-6 levels in patients with primary Sjogren's syndrome, Rheumatol Int, 18, 125, 10.1007/s002960050070 Tishler, 1998, Elevated tear interleukin-6 levels in patients with Sjogren syndrome, Ophthalmology, 105, 2327, 10.1016/S0161-6420(98)91236-2 Grisius, 1997, Salivary and serum interleukin 6 in primary Sjogren's syndrome, J Rheumatol, 24, 1089 Hulkkonen, 2001, Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease, Rheumatology (Oxford), 40, 656, 10.1093/rheumatology/40.6.656 Szyszko, 2011, Salivary glands of primary Sjogren's syndrome patients express factors vital for plasma cell survival, Arthritis Res Ther, 13, 10.1186/ar3220 Sugaya, 2011, Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface, Jpn J Ophthalmol, 55, 277, 10.1007/s10384-011-0002-x Benchabane, 2016, A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjogren's syndrome, Int J Immunopathol Pharmacol, 29, 386, 10.1177/0394632016651273 Meiners, 2014, Abatacept treatment reduces disease activity in early primary Sjogren's syndrome (open-label proof of concept ASAP study), Ann Rheum Dis, 73, 1393, 10.1136/annrheumdis-2013-204653 Adler, 2013, Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjogren's syndrome: a pilot study, Arthritis Care Res (Hoboken), 65, 1862, 10.1002/acr.22052 Moerman, 2017, Detailed analysis of the articular domain in patients with primary Sjogren syndrome, J Rheumatol, 44, 292, 10.3899/jrheum.160459 A study to assess the efficacy and safety of abatacept in adults with active primary. Sjogren's syndrome. Available from: https://clinicaltrials.gov/ct2/show/NCT02915159 [accessed 28.12.17]. Randomized D-b, placebo-controlled phase III study to assess the efficacy and safety of abatacept in patients with primary Sjögren's syndrome (ASAP III Study, Abatacept Sjögren Active Patients Phase III Study). Available from: https://clinicaltrials.gov/ct2/show/NCT02067910 [accessed 28.12.17]. Justet, 2015, Tocilizumab for refractory organising pneumonia associated with Sjogren's disease, BMJ Case Rep, 10.1136/bcr-2014-209076 Komai, 2016, Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: a case report, Mod Rheumatol, 26, 294, 10.3109/14397595.2013.861333 Seror, 2011, EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome, Ann Rheum Dis, 70, 968, 10.1136/ard.2010.143743 Fisher, 2017, Standardisation of labial salivary gland histopathology in clinical trials in primary Sjogren's syndrome, Ann Rheum Dis, 76, 1161, 10.1136/annrheumdis-2016-210448 Guellec, 2013, Diagnostic value of labial minor salivary gland biopsy for Sjogren's syndrome: a systematic review, Autoimmun Rev, 12, 416, 10.1016/j.autrev.2012.08.001 Seror, 2016, Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI), Ann Rheum Dis, 75, 382, 10.1136/annrheumdis-2014-206008 Wolffsohn, 2017, TFOS DEWS II Diagnostic Methodology report, Ocul Surf, 15, 539, 10.1016/j.jtos.2017.05.001 Hammitt, 2017, Patient burden of Sjogren's: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity, RMD Open, 3, 10.1136/rmdopen-2017-000443 Seror, 2015, EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide, RMD Open, 1, 10.1136/rmdopen-2014-000022 Seror, 2015, Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI), Ann Rheum Dis, 74, 859, 10.1136/annrheumdis-2013-204615